[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07037836":3,"trial-entities:NCT07037836":160,"trial-summary:NCT07037836":164},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":27,"interventions":30,"primary_outcomes":37,"secondary_outcomes":60,"sex":95,"minimum_age":96,"maximum_age":97,"healthy_volunteers":14,"eligibility_criteria":98,"std_ages":125,"locations":128,"central_contacts":150,"overall_officials":157,"references":158,"see_also_links":159},"NCT07037836","PRO00118083","Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia","RECRUITING","2027-07-01","2026-08","2026-08-27","2025-09-29","Bastiaan Driehuys","OTHER",false,"The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \\[DLCO\\] ≥45%).\n\nThe main questions it aims to answer are:\n\n1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)?\n2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \\[RBC\\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)?\n3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil?\n\nParticipants will:\n\n* Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated.\n* Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange.\n* Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study.\n* Be monitored for adverse events, with a phone check-in midway through and after the treatment period.","This is a single-arm, proof-of-concept study evaluating the effects of inhaled Treprostinil (Tyvaso nebulizer) on regional gas exchange and capillary blood oxygenation in patients with chronic obstructive pulmonary disease (COPD) and hypoxemia. The study will enroll 10 outpatient subjects aged ≥40 with a chronic bronchitis phenotype, confirmed COPD diagnosis, and a diffusing capacity of the lungs for carbon monoxide (DLCO) ≥45% predicted. All participants will receive inhaled Treprostinil via a 4-week dose titration protocol (starting at 3 breaths four times daily and increasing to 6 breaths as tolerated).\n\nThe primary objectives are to \"determine the effects of inhaled Treprostinil on regional gas exchange and capillary blood oxygenation as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI), including ventilation defect percentage (VDP), membrane defect percentage, red blood cell (RBC) transfer defect percentage and normalized RBC oscillation amplitude and RBC frequency shift,\" and to \"determine whether pre-treatment VDP, membrane defect percentage, RBC transfer defect percentage, RBC chemical shift and normalized RBC oscillation amplitude predict a positive response to inhaled Treprostinil.\"\n\nAssessments will include HP129Xe MRI, spirometry with DLCO, 6-minute walk testing (6MWT), and echocardiography at baseline and after 4 weeks. Data will be analyzed for changes in regional lung function and oxygenation. Safety monitoring will focus on known adverse effects of inhaled Treprostinil including \"cough, headache, hypotension, oropharyngeal pain, throat irritation and nausea,\" and will address more serious risks observed in the PERFECT trial (COPD exacerbation, respiratory failure, myocardial infarction, and death). By selecting subjects with DLCO ≥45% predicted and using a shorter 4-week treatment duration with titrated dosing, the study aims to mitigate these risks.",[18,19],"COPD (Chronic Obstructive Pulmonary Disease)","Hypoxemia",[21,22,19],"Tyvaso","COPD","INTERVENTIONAL","TREATMENT",[26],"PHASE2",{"count":28,"type":29},10,"ESTIMATED",[31],{"type":32,"name":33,"description":34,"armGroupLabels":35},"DRUG","Inhaled Treprostinil (Tyvaso Nebulizer)","Participants will receive inhaled Treprostinil (Tyvaso nebulizer), 6 µg per breath, administered four times daily for 4 weeks. The starting dose will be 3 breaths per session. The dose will increase by 1 breath per session each week, as tolerated, to a target of 6 breaths per session by week 4. If adverse effects occur, participants will remain at the highest tolerated dose. The drug will be administered using the Tyvaso inhalation system provided by United Therapeutics. No changes to baseline COPD maintenance medications are allowed during the treatment period. Participants will be monitored for safety throughout the study.",[36],"Inhaled Treprostinil in COPD Patients With Hypoxemia and Preserved DLCO",[38,42,45,48,51,54,57],{"measure":39,"description":40,"timeFrame":41},"Ventilation Defect Percentage (VDP) on HP129XeMRI","Defined as the region with ventilation signals \\\u003C mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume.","Baseline and 4 weeks post-Tyvaso",{"measure":43,"description":44,"timeFrame":41},"Membrane Defect Percentage on HP129XeMRI","Defined as the region with membrane signals \\\u003C mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume.",{"measure":46,"description":47,"timeFrame":41},"Low Membrane Region Percentage on HP129XeMRI","Defined as the region with membrane signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume.",{"measure":49,"description":50,"timeFrame":41},"RBC Transfer Defect Percentage on HP129XeMRI","Defined as the region with RBC transfer signals \\\u003C mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume.",{"measure":52,"description":53,"timeFrame":41},"Low RBC Transfer Region Percentage on HP129XeMRI","Defined as the region with RBC transfer signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume.",{"measure":55,"description":56,"timeFrame":41},"RBC Oscillation Amplitude Normalized for RBC Transfer Defect","Measured using HP129XeMRI spectroscopy as a surrogate for pulmonary vascular resistance, normalized to RBC transfer signal intensity.",{"measure":58,"description":59,"timeFrame":41},"RBC Chemical Shift on HP129XeMRI Spectroscopy","Frequency shift in RBC signal reflecting capillary blood oxygenation, measured using HP129XeMRI spectroscopy.",[61,65,68,71,74,77,80,83,86,89,92],{"measure":62,"description":63,"timeFrame":64},"Nadir SpO₂ During 6MWT","Lowest oxygen saturation (SpO₂) recorded during the 6-minute walk test, measured by pulse oximetry. The test is performed on room air unless SpO₂ drops below 89%, at which point supplemental oxygen is administered to maintain SpO₂ ≥89%.","Baseline and 4 weeks post-Tyvaso treatment",{"measure":66,"description":67,"timeFrame":64},"Supplemental Oxygen Flow During 6MWT","Oxygen flow rate in liters per minute required to maintain SpO₂ ≥89% during the 6-minute walk test if room air is insufficient.",{"measure":69,"description":70,"timeFrame":64},"6-Minute Walk Distance (6MWD)","Total distance walked in meters during the 6-minute walk test, following ATS guidelines.",{"measure":72,"description":73,"timeFrame":64},"Dyspnea Score During 6MWT","Subjective rating of dyspnea severity on a 1-10 scale reported by participants at the end of the 6-minute walk test.",{"measure":75,"description":76,"timeFrame":64},"Peak Heart Rate (% Predicted) During 6MWT","Highest heart rate achieved during the 6-minute walk test, expressed as a percentage of predicted maximum heart rate.",{"measure":78,"description":79,"timeFrame":64},"Forced Expiratory Volume in 1 Second (FEV1) - Absolute and % Predicted","EV1 measured in liters and as a percentage of predicted value, assessed by spirometry.",{"measure":81,"description":82,"timeFrame":64},"Forced Vital Capacity (FVC) - Absolute and % Predicted","FVC measured in liters and as a percentage of predicted value, assessed by spirometry",{"measure":84,"description":85,"timeFrame":64},"Total Lung Capacity (TLC) - Absolute and % Predicted","TLC measured in liters and as a percentage of predicted value, assessed by lung volume testing.",{"measure":87,"description":88,"timeFrame":64},"Residual Volume (RV) - Absolute and % Predicted","RV measured in liters and as a percentage of predicted value, assessed by lung volume testing.",{"measure":90,"description":91,"timeFrame":64},"Diffusing Capacity for Carbon Monoxide (DLCO) - Absolute and % Predicted","DLCO measured in mL\u002Fmin\u002FmmHg and as a percentage of predicted value, assessed by single-breath method.",{"measure":93,"description":94,"timeFrame":64},"Carbon Monoxide Transfer Coefficient (KCO) - Absolute and % Predicted","KCO measured in mL CO\u002Fmin\u002FmmHg\u002FL and as a percentage of predicted value, derived from DLCO and alveolar volume.","ALL","40 Years",null,{"inclusion":99,"exclusion":108,"raw_text":124},[100,101,102,103,104,105,106,107],"Outpatients of either gender, age ≥ 40.","Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).","Current or former cigarette smokers with a smoking history of 20 or more pack-years.","Clinical diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by spirometry demonstrating forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \\\u003C 0.70, pre-bronchodilator FEV1 ≥ 30% predicted, and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 45% predicted.","On stable maintenance COPD medications including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), combination inhalers, azithromycin, or roflumilast (with no changes over the past 3 months).","Patients with hypoxemia, evidenced by the use of supplemental oxygen at rest or during exercise (≤ 4 liters\u002Fminute).","Willing and able to give informed consent and adhere to visit and protocol schedules (consent must be obtained prior to any study procedures).","Women of childbearing potential must have a negative serum pregnancy test, confirmed prior to participation in this investigational protocol.",[109,110,111,112,113,114,115,116,117,118,119,120,121,122,123],"Upper respiratory tract infection within 6 weeks (participants may be rescreened after this period).","History of lung resection surgery or pleural decortication.","Previous history of pneumothorax.","Imaging evidence of interstitial lung disease, occupational lung disease, or chronic infectious lung disease.","History of asthma.","History of exposure to occupational or environmental hazards known to cause lung disease.","Positive pregnancy test for women of childbearing potential.","Major chronic illness that, in the judgment of the study physician, would interfere with participation in the study.","Contraindications to MRI based on screening questionnaire responses.","Participant is pregnant or lactating.","Respiratory illness of bacterial or viral etiology within 6 weeks prior to MRI.","Known cardiac arrhythmia.","Participant does not fit into the hyperpolarized xenon-129 (\\^129Xe) vest coil used for MRI.","Participant cannot hold their breath for 10 seconds.","Participant is unlikely to comply with instructions during imaging.","Inclusion Criteria\n\n* Outpatients of either gender, age ≥ 40.\n* Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).\n* Current or former cigarette smokers with a smoking history of 20 or more pack-years.\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by spirometry demonstrating forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \\\u003C 0.70, pre-bronchodilator FEV1 ≥ 30% predicted, and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 45% predicted.\n* On stable maintenance COPD medications including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), combination inhalers, azithromycin, or roflumilast (with no changes over the past 3 months).\n* Patients with hypoxemia, evidenced by the use of supplemental oxygen at rest or during exercise (≤ 4 liters\u002Fminute).\n* Willing and able to give informed consent and adhere to visit and protocol schedules (consent must be obtained prior to any study procedures).\n* Women of childbearing potential must have a negative serum pregnancy test, confirmed prior to participation in this investigational protocol.\n\nExclusion Criteria\n\n* Upper respiratory tract infection within 6 weeks (participants may be rescreened after this period).\n* History of lung resection surgery or pleural decortication.\n* Previous history of pneumothorax.\n* Imaging evidence of interstitial lung disease, occupational lung disease, or chronic infectious lung disease.\n* History of asthma.\n* History of exposure to occupational or environmental hazards known to cause lung disease.\n* Positive pregnancy test for women of childbearing potential.\n* Major chronic illness that, in the judgment of the study physician, would interfere with participation in the study.\n\nFor Magnetic Resonance Imaging (MRI):\n\n* Contraindications to MRI based on screening questionnaire responses.\n* Participant is pregnant or lactating.\n* Respiratory illness of bacterial or viral etiology within 6 weeks prior to MRI.\n* Known cardiac arrhythmia.\n* Participant does not fit into the hyperpolarized xenon-129 (\\^129Xe) vest coil used for MRI.\n* Participant cannot hold their breath for 10 seconds.\n* Participant is unlikely to comply with instructions during imaging.",[126,127],"ADULT","OLDER_ADULT",[129],{"facility":130,"status":7,"city":131,"state":132,"zip":133,"country":134,"contacts":135,"geoPoint":147},"Duke Asthma Allergy and Airway Center","Durham","North Carolina","27705","United States",[136,141,144],{"name":137,"role":138,"phone":139,"email":140},"Savannah Barbieri","CONTACT","919613740","savannah.barbieri@duke.edu",{"name":142,"role":138,"email":143},"Jessica Shier","jessica.shier@duke.edu",{"name":145,"role":146},"Yuh-Chin Huang, MD","PRINCIPAL_INVESTIGATOR",{"lat":148,"lon":149},35.99403,-78.89862,[151,155],{"name":152,"role":138,"phone":153,"email":154},"Yuh-Chin Huang, M.D., M.H.S., MD","919-684-3069","yuhchin.huang@duke.edu",{"name":137,"role":138,"phone":156,"email":140},"919-613-0740",[],[],[],{"nct_id":4,"conditions":161,"biomarkers":163},[162,19],"Chronic Obstructive Pulmonary Disease",[],{"nct_id":4,"found":165,"summary":166,"prompt_version":176},true,{"design":167,"status":168,"heading":169,"summary":170,"follow_up":171,"word_count":172,"commitments":173,"compensation":174,"drugs_mentioned":175},"This is a single-arm study, meaning all 10 participants will receive the same treatment. It is a proof-of-concept study, which means it's an early look at how the treatment works.","completed","Inhaled Treprostinil for COPD with Hypoxemia","This study is testing whether inhaled Treprostinil (Tyvaso Nebulizer) can improve how oxygen is delivered and blood flows in the lungs of adults (age 40 and older) who have chronic obstructive pulmonary disease (COPD) and low oxygen levels (hypoxemia). Participants will receive inhaled Treprostinil four times a day for four weeks, with the dose gradually increasing as tolerated. Researchers will use a special MRI scan (HP129Xe MRI) to see if the treatment improves lung function, specifically looking at how well air and blood move through the lungs. You may be eligible if you have COPD with chronic bronchitis, a history of smoking, and a certain level of lung function.","Assessments are measured at Baseline and 4 weeks post-Tyvaso, indicating a follow-up period of at least 4 weeks.",109,"You would receive inhaled Treprostinil four times daily for four weeks. You would also have assessments like HP129Xe MRI, lung function tests (spirometry with DLCO), a 6-minute walk test, and an echocardiogram at the beginning and end of the 4-week treatment period.","Not stated in the trial record.",[33],"v2"]